A team of US-based scientists have found "a probable causal connection" between a form of bacteria found in the human gut and the onset of depression.Carried out by a team from Harvard University and Massachusetts General Hospital,

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of interest in everyday activities, appetite changes, sleep disturbances and, in extreme cases,

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in depression in those of European and non-European ancestry.

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences.

Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some cases of major depressive disorder. Incorporation of an environmental contaminant into a molecule the bacterium makes appears to activate inflammation, which is known to contribute to disease development.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.